Valar Labs

Valar Labs is a biotechnology company based in Palo Alto, founded in 2021.

The company specializes in AI-driven precision oncology diagnostics, focusing on analyzing pathology slides of solid tumors to assist physicians and patients in making informed cancer treatment decisions. Valar Labs operates in the healthcare sector, aiming to reduce uncertainty in oncology through its innovative diagnostic tools. The company's primary offering is an AI-powered software platform that conducts clinical-grade deep learning analysis on patient pathology slides. One of its key products, Vesta, is designed to help urologists predict treatment responses in patients with high-grade non-muscle invasive bladder cancer. Valar Labs partners with pharmaceutical firms, oncologists, and cancer patients across Europe, the United States, and Asia Pacific, providing evidence-based insights to improve patient outcomes. Valar Labs has successfully raised $22 million in Series A funding, bringing its total funding to approximately $26 million. The company is valued at around $50.51 million and employs about 27 people, all dedicated to enhancing cancer care through advanced diagnostic intelligence.